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In this study, we tested the hypothesis that a CB1
TMH3-4-5-6 aromatic microdomain, which includes
F3.25(190), F3.36(201), W5.43(280), andW6.48(357), is cen-
trally involved in CB1 receptor activation, with the
F3.36(201)/W6.48(357) interaction key to the mainte-
nance of the CB1-inactive state. We have shown previ-
ously that when F3.36(201), W5.43(280), and W6.48(357)
are individually mutated to alanine, a significant reduc-
tion in ligand binding affinity is observed in the pres-
ence of WIN 55,212-2 and SR141716A but not CP55,940
and anandamide. In the work presented here, we report
a detailed functional analysis of the F3.36(201)A,
F3.25(190)A, W5.43(280)A, and W6.48(357)A mutant
receptors in stable cell lines created in HEK cells for
agonist-stimulated guanosine 5-3-O-(thio)triphosphate
(GTPS) binding and GIRK1/4 channel current effects in
Xenopus oocytes where the mutant proteins were ex-
pressed transiently. The F3.36(201)A mutation showed
statistically significant increases in ligand-independent
stimulation of GTPS binding versus wild type CB1, al-
though basal levels for the W6.48(357)A mutant were not
statistically different from wild type CB1. F3.36(201)A
demonstrated a limited activation profile in the pres-
ence of multiple agonists. In contrast, enhanced agonist
activation was produced by W6.48(357)A. These results
suggest that a F3.36(201)/W6.48(357)-specific contact is
an important constraint for the CB1-inactive state that
may need to break during activation. Modeling studies
suggest that the F3.36(201)/W6.48(357) contact can exist
in the inactive state of CB1 and be broken in the acti-
vated state via a 1 rotamer switch (F3.36(201) trans,
W6.48(357) g) 3 (F3.36(201) g, W6.48(357) trans). The
F3.36(201)/W6.48(357) interaction therefore may repre-
sent a “toggle switch” for activation of CB1.
The cannabinoid CB1 receptor belongs to the class A rho-
dopsin-like family of G protein-coupled receptors (GPCRs)1
(see helix net, Fig. 1) (2). The availability of high resolution
crystal structures of rhodopsin (Rho) (3, 4) (Protein Data
Bank accession code 1GZM) and the availability of biophysi-
cal data on the conformational changes that occur when
rhodopsin and other class A receptors are activated (6–8)
have greatly aided the study of structure-function relation-
ships in class A GPCRs. Ballesteros et al. (9) have proposed
that “structural mimicry” may occur in GPCRs such that
different amino acids or alternate microdomains in class A
receptors (e.g. the amine receptors) can support similar de-
viations from the regular -helical structure seen in Rho,
thereby resulting in similar tertiary structures. In the work
presented here, we provide evidence that “structural (func-
tional) mimicry” by alternate microdomains may also support
the core function of signaling activation through transmem-
brane helix conformational change in the class A family.
There is a growing body of evidence in the literature that
activation of GPCRs is accompanied by rigid domain motions
and rotations of transmembrane helices (TMHs) 3 and 6 (6–8).
At their intracellular ends, TMHs 3 and 6 in Rho are con-
strained by an E3.49(134)/R3.50(135)/E6.30 (247) salt bridge
that limits the relative mobility of the cytoplasmic ends of
TMH3 and TMH6 in the inactive state (3) and acts like an
“ionic lock” (10, 11). During activation, P6.50 of the highly
conserved CWXPmotif in TMH6 of GPCRs may act as a flexible
hinge, permitting TMH6 to straighten upon activation, moving
its intracellular end away from TMH3 and upwards toward the
lipid bilayer (12).
Khorana and co-workers (13) have reported that even in the
dark (inactive) state of Rho, only some strong constraints exist,
whereas the majority of the molecule experiences conforma-
tional flexibility. Therefore, light activation of Rho does not
require the breaking and forming of thousands of specific con-
tacts within nanoseconds, rather only a few specific contacts
restricting the inactive state, including indole side chain con-
tacts of tryptophan residues, need to break on activation. These
changes can then be transmitted through the entire membrane
protein because of its dynamic plasticity. One of the tryptophan
residues that Khorana and co-workers (13) have reported to be
restricted is W6.48(265). In the dark (inactive) state of Rho, the
-ionone ring of 11-cis-retinal is close to W6.48(265) of the
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CWXP motif on TMH F and helps constrain it in a 1  g
conformation (3). In the light-activated state, the -ionone
ring moves away from TMH F and toward TMH D where it
resides close to A4.58(169) (14). This movement releases the
constraint on W6.48(265), making it possible for W6.48(265)
to undergo a conformational change. Lin and Sakmar (15)
reported that perturbations in the environment of
W6.48(265) of Rho occur during the conformational change
concomitant with receptor activation. This suggests that the
conformation of W6.48(265) when Rho is in its inactive/
ground state (R; 1  g) changes during activation (i.e.
W6.48(265) 1 g 3 trans) (16).
In the class A cationic neurotransmitter receptors, a highly
conserved cluster of aromatic amino acids is found on TMH6
that faces the binding site crevice bracketing W6.48 (F6.44,
W6.48, F6.51, and F6.52) (16). Shi et al. (16) have proposed that
an aromatic at 6.52 (F6.52) in the 2-adrenergic receptor may
serve to constrain W6.48 in its inactive state (i.e. g 1) and is
part of a rotamer toggle switch (C6.47 trans/W6.48 g/F6.52
g3 C6.47 g/W6.48 trans/F6.52 trans) for activation of this
receptor.
Restriction of W6.48 by a TMH6 aromatic cluster is not
possible in the cannabinoid receptors, as the CB1 receptor
has leucines at 6.44, 6.51, and 6.52. Instead, the CB1 receptor
contains a microdomain of aromatic residues that face into
the ligand-binding pocket in the TMH3-4-5-6 region, includ-
ing F3.25(190), F3.36(201), W4.64(256), Y5.39(276),
W5.43(280), and W6.48(357) (Fig. 2). In work reported here,
we suggest that the F3.36(201)/W6.48(357) interaction may
act as a mimic of the 11-cis-retinal/W6.48 interaction in the
Rho dark state and may serve as the “toggle switch” for CB1
activation, with F3.36(201) 1 trans/W6.48(357) 1 g repre-
senting the inactive (R) and F3.36(201) 1 g/W6.48(357) 1
trans representing the active (R*) state of CB1. Modeling,
mutation, and functional studies undertaken to test the im-
portance of the TMH3-4-5-6 aromatic microdomain in ligand
recognition and in the conformational changes that accom-
pany activation of CB1 suggest that a F3.36(201)/W6.48(357)-
specific contact is an important constraint for the CB1-
inactive state.
FIG. 2. Models of the CB1 R and R* states in the TMH3-4-5-6
region (in the absence of ligand) are illustrated here (1). A, in the
R state model, a salt bridge can form between K3.28(193) and D6.58
(367) (shown in green). F3.25(190) (shown in gray) is close enough to
have a cation- interaction with K3.28(193). A microdomain of clus-
tered aromatic residues (shown in yellow) W6.48(357)/F3.36(201)/
W5.43(280)/Y5.39(276)/W4.64(256) exists in the CB1 TMH3-4-5-6 re-
gion. B, the conformational changes that occur upon receptor activation
(R 3 R* transition) result in rotations of TMH3 and -6, as well as a
change in the conformation of TMH6 (by moderation of its proline kink
angle) (6–8, 10). The K3.28(193)-D6.58(367) salt bridge is broken (res-
idues illustrated in green) and K3.28(193) and F3.25(190) (in gray) are
now oriented toward the TMH2/7 region of CB1. The aromatic cluster
present in the inactive state model also undergoes re-arrangement,
with W6.48(357)/W5.43(280)/Y5.39(276)/W4.64(256) (shown in yellow)
maintaining an extended cluster, whereas F3.36(201) (yellow) is no
longer part of this cluster.
FIG. 1. A helix net representation of the sequence of the mouse CB1 receptor. The amino acids of the TMH3-4-5-6 aromatic microdomain
are highlighted in boldface.
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EXPERIMENTAL PROCEDURES
Molecular Modeling
Amino Acid Numbering System—In the discussion of receptor resi-
dues below, the amino acid numbering scheme proposed by Ballesteros
and Weinstein (17) is used. In this numbering system, the most highly
conserved residue in each transmembrane helix (TMH) is assigned a
locant of 0.50. This number is preceded by the TMH number and
followed in parentheses by the sequence number. All other residues in
a TMH are numbered relative to this residue. In this numbering sys-
tem, for example, the most highly conserved residue in TMH2 of the
mouse CB1 receptor is D2.50(164). The residue that immediately pre-
cedes it is A2.49(163). Fig. 1 serves as a reference for this numbering
system in mouse CB1.
Definition of Rotameric State of 1—Different nomenclatures have
been used to define the rotameric state of side chain torsion angles. The
nomenclature employed here for the 1 torsion angle is that described
by Shi et al. (16). When the heavy atom at the  position is opposite to
the backbone nitrogen when viewed from the -carbon to the -carbon,
the 1 is defined to be trans. When the heavy atom at the  position is
opposite to the backbone carbon when viewed from the -carbon to the
-carbon, the 1 is defined to be gauche (g). When the heavy atom at
the  position is opposite to the -hydrogen when viewed from the
-carbon to the -carbon, the 1 is defined to be gauche (g). By using
this nomenclature system, the side chain conformations discussed here
are categorized into g (0° 1 120°), trans (120° 1 240°), or g
(240°  1  360°).
Conformational Memories Studies of TMH6 and the W6.48A Mutant
TMH6—In order to explore the consequences of the W6.48A mutation
upon the conformation of TMH6, we used the conformational memories
(CM) method (18), a method that employs multiple Monte Carlo/simu-
lated annealing random walks and the Amber* force field. Conforma-
tional memories has been shown to converge in a very practical number
of steps and to be capable of overcoming energy barriers efficiently. By
using CM, the conformational properties of a helix can be fully charac-
terized by the free energy of each of the conformations that the helix can
adopt, and this property includes not only the intrinsic energy of each
conformational state but also the probability that the helix will adopt
each particular conformation relative to all other ones accessible in an
equilibrated thermodynamic ensemble.
The calculation is performed in two phases. In the first phase, re-
peated runs of Monte Carlo/simulated annealing are carried out to map
the entire conformational space of the helix. In the second phase, new
Monte Carlo/simulated annealing runs are performed only in the pop-
ulated regions identified in the first phase of the calculation.
WT TMH6 Versus TMH6 W6.48A Mutant—The CB1 TMH6 (from
residue 6.30 to residue 6.57, DIRLAKTLVLILVVLIICWGPLLAIMVY)
and the TMH6 W6.48A mutant (DIRLAKTLVLILVVLIICAGPL-
LAIMVY) were built using MacroModel (19). In the Rho 2.8-Å crystal
structure (3), 1 of W6.48 is g. In order to be consistent with this
result, 1  g, 60° was chosen as the starting conformation for
W6.48(357) in the WT TMH6 run. Our previous CM studies of TMH6
have suggested that when C6.47(356) adopts a trans conformation (1
180°) and forms a hydrogen bond with the backbone of TMH6, TMH6
exhibits its greatest flexibility. In the studies reported here, the 1 of
C6.47(356) was set to trans. The s for all other amino acids in TMH6
were left at the default values used by MacroModel when an -helix is
built (19). The charges on all charged residues in each TMH6 studied
were reduced to one-third of their values to prevent artifacts during the
CM runs.
All calculations were performed using a distance-dependent dielec-
tric. Each TMH6 was first minimized using the Amber* forcefield in
MacroModel (19). For WT CB1 TMH6 73 torsion angles were allowed to
vary during the CM runs, whereas 71 torsion angles were allowed to
vary in the CB1 TMH6 W6.48(357)A mutant run. These included all
helix backbone s and s, as well as amino acid side chain torsion
angles for L6.39(348) to I6.54(363) (excluding 1 dihedrals on
-branched residues and 2 on C6.47(356) in this span). The backbone
s and s for I6.46(355) through P6.50(359) (i.e. the turn before
P6.50(359)) were allowed to vary 50° from their minimized values. All
other backbone torsions were allowed to vary  10°. The 1 and 2 for
W6.48(357) in WT TMH6 and the 1 for C6.47(356) (in both the WT and
W6.48(357)A mutant runs) were allowed to vary 60°. The 2 for
C6.47(356) was not allowed to vary in either run. All other side chain
torsion angles were allowed to vary  180° without constraints. The
calculation was performed in two phases as indicated below.
Exploratory Phase—In the exploratory phase, a random walk was
used to identify the region of conformational space that is populated for
each torsion angle studied. Starting at a temperature of 2070 K, 20,000
steps were applied to the rotatable bonds with cooling in 18 steps to a
final temperature of 310 K. Trial conformations were generated at each
temperature by randomly picking three torsion angles from the set of 73
(71 in the W6.48A mutant) and changing each angle by a random value
within the range set in the calculation (see above). After each step, the
generated trial conformation was either accepted or rejected using the
Metropolis criterion. This calculation was repeated for a total of 100
cycles. Accepted conformations were used to map the conformational
space of TMH6 by creating “memories” of values for each torsion angle
that were accepted.
Biased Annealing Phase—In the second phase of the CM calculation,
the only torsion angle moves attempted were those that would keep the
angle in the “populated conformational space” mapped in the explora-
tory phase. The biased annealing phase began at a temperature of 722
K cooling to 310 K in 8 steps. 100 structures were written out at 310 K.
Analysis of Output—Finally, the output of 100 structures at 310 K
was clustered using X-Cluster in MacroModel (19). This program re-
orders the structures according to their root mean square deviation and
groups the structures into families of similar conformers. The resulting
100 structures from CMwere also analyzed using the program, ProKink
(20). This program, which is embedded in the Simulaid Conversion
program,2 was used to calculate the face shift, wobble, and bend angles
of each helix. Statistically significant differences between the face shift,
wobble, and bend angles of the R and R* CB1 WT versusW6.48A R and
R* helix families were evaluated in the two-sample independent t test
computed using OriginPro version 7 (Origin Lab Corp.).
Models of CB1 R and R* States—In the present study, the literature
on GPCR activation discussed above was used to generate an R* CB1
TMH bundle from a model of the inactive (R) CB1 receptor based on the
2.8-Å crystal structure of rhodopsin (3). The creation of these two forms
of CB1 is described briefly below.
Model of Inactive State (R) Form of CB1—A model of the R form of
CB1 was created using the 2.8-Å crystal structure of bovine Rho (3).
First, the sequence of the mouse CB1 receptor (22) (see Fig. 1) was
aligned with the sequence of bovine Rho using the same highly con-
served residues as alignment guides that were used initially to generate
our first model of CB1 (23). TMH5 in CB1 lacks the highly conserved
proline in TMH5 of Rho. Therefore, the sequence of CB1 in the TMH5
region was aligned with that of Rho as described previously using its
hydrophobicity profile (23). The mouse CB1 sequence (22) is 97.7%
identical to the human CB1 sequence (2) overall and 100% identical
within the transmembrane regions. The mouse sequence is one residue
longer (473 residues) than the human sequence (472 residues) due to an
additional residue in the N terminus.
Initial helix ends for mouse CB1 were chosen in analogy with those of
Rho (3). With the exception of TMH1, these helix ends were found to be
within one turn of the helix ends originally calculated by us and re-
ported in 1995 (23). Two changes dictated by the CB1 sequence were
made in the helix ends. The shortness of the E1 loop region in CB1
necessitated starting TMH3 at 3.23 (N3.23(188) to R3.56(221)). The
break in helicity caused by the GWNC sequence motif on the extracel-
lular end of TMH4 necessitated that TMH4 end at 4.62 instead of 4.66
(as is found in Rho). Changes to the general Rho structure that were
necessitated by sequence divergences included the absence of helix-
kinking proline residues in TMH1 and TMH5, the lack of a GG motif in
TMH2, as well as the presence of extra flexibility in TMH6 (24). Our
recent conformational memories study of TMH6 in CB1 revealed that
TMH6 in CB1 has high flexibility due to the small size of residue 6.49 (a
glycine) immediately preceding Pro 6.50. The conformer selected from
our CM results for inclusion in the CB1 R bundle (Pro kink angle 
53.1o) was chosen so that R3.50(215) and D6.30(339) could form a salt
bridge at the intracellular ends of TMH3 and -6 in the CB1 TMH
bundle. An analogous salt bridge has been shown to be an important
stabilizer of the inactive state of the 2-adrenergic receptor, the 5HT-2a
receptor (10), and to be present in Rho (3). Because of the extreme
flexibility of TMH6 in CB1, we have proposed that an additional
TMH3–6 salt bridge, K3.28(193)–D6.58(367), stabilizes the inactive
state on the extracellular side of the TMH bundle (25).
Model of Active (R*) Form of CB1—Based upon experimental results
for rhodopsin and the 2-adrenergic receptor (6, 10, 15, 26), the R*
(active) CB1 bundle was created from the inactive (R) model of CB1 by
substituting a less kinked TMH6 (21.8o kink angle) from our CM results
(25)for which the R3.50(215) and D6.30(339) salt bridge would be bro-
ken due to the movement of the intracellular end of TMH6 away from
2 M. Mezei, personal communication.
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that of TMH3 and out into lipid (10). Rotations of both TMH3 and
TMH6 were also central to the creation of the R* model. The details of
these rotations are presented elsewhere (24).
Preparation of Helices—Each helix of the model was capped as the
acetamide at its N terminus and as the N-methyl amide at its C
terminus. Ionizable residues in the first turn of either end of the helix
were neutralized, as were any lipid facing charged residues. Ionizable
residues were considered charged if they appeared anywhere else in the
helix.
Energy Minimization, Unoccupied Receptor States—The energy of
the CB1 R or CB1 R* TMH bundle complex was minimized using the
AMBER* united atom force field in Macromodel 6.5 (Schro¨dinger Inc.,
Portland, OR). A distance-dependent dielectric, 8.0-Å extended non-
bonded cut-off (updated every 10 steps), 20.0-Å electrostatic cut-off,
4.0-Å hydrogen bond cut-off, and explicit hydrogens on sp2 carbons
were used. The first stage of the calculation consisted of 2000 steps of
Polak-Ribier conjugate gradient (CG) minimization in which a force
constant of 225 kJ/mol was used on the helix backbone atoms in order
to hold the TMH backbones fixed, while permitting the side chains to
relax. The second stage of the calculation consisted of 100 steps of CG
in which the force constant on the helix backbone atoms was reduced
to 50 kJ/mol in order to allow the helix backbones to adjust. Stages
one and two were repeated with the number of CG steps in stage two
incremented from 100 to 500 steps until a gradient of 0.001 kJ/
(molÅ2) was reached. This same protocol was followed for the
W6.48(357)A TMH bundle.
Assessment of Aromatic Stacking Interactions—Residues were desig-
nated here as participating in an aromatic stacking interaction if sub-
ject rings had centroid to centroid distances (d) between 4.5 and 7.0Å.
These interactions were further classified as “tilted t” arrangements if
30°    90° and as parallel arrangements for   30° (where  is the
angle between normal vectors of interacting rings) (27). Parallel ar-
rangements were considered favorable only if the interacting rings were
offset from each other (28). All measurements were made using
MacroModel 8.1.
Assessment of Cation- Interactions—In their study of cation- in-
teractions in the protein data bank, Gallivan and Dougherty (29) con-
sidered a cation- interaction to be present in structures when both r 
10 Å and r  10 Å, where r is the distance between the ammonium
nitrogen (NZ) of the protonated residue and the aromatic ring centroid,
and r is the distance between CE of the protonated residue (in the case
here, a Lys) and the aromatic ring centroid (29). However, these inves-
tigators reported that in 88% of the cation- interactions considered,
r  5 Å and r  5 Å. A cation- interaction was judged to be present in
the work presented here if r  5 Å and r  5 Å. The r and r distances
were measured here using MacroModel 8.1.
Ligand Conformations and Docking Positions—The binding site con-
formations and anchoring interactions inside the receptor used for each
ligand discussed here are based on our recently published work (1).
Mutation Studies
Materials—SR141716A and CP55,940 were obtained from the Na-
tional Institute on Drug Abuse. WIN 55,212-2 was purchased from RBI
(Natick, MA), and anandamide was purchased from Tocris (Ellisville, MI).
Mutagenesis, Cell Culture, and Radioligand Binding—The cell lines
used in this study have been described previously (1). Site-directed
mutations were introduced into mouse CB1 in pcDNA3 at the desig-
nated sites using the QuikChange mutagenesis technique (Stratagene,
La Jolla, CA). Stable cell lines were created by transfection of wild type
or mutant CB1pcDNA3 into HEK 293 cells by the LipofectAMINE
reagent (Invitrogen) and cultured as described previously (30). Cell
lines containing moderate to high levels of receptor mRNA, assessed by
Northern analysis, were tested for receptor binding and signal trans-
duction properties. Receptor binding was determined as described
previously (1). Cell lines with the most similar receptor expression
profile, as ascertained by Bmax values, were chosen for further analysis
(Table I).
[35S]GTPS Binding Assay—The basal activity and the ability of
various cannabinoids to stimulate the wild type CB1 receptor or the
mutant receptors were tested with [35S]GTPS binding. Cells were har-
vested in phosphate-buffered saline containing 1 mM EDTA and centri-
fuged at 500  g for 5 min. The cell pellet was homogenized and centri-
fuged at 50,000  g for 10 min at 4 °C. The pellet was resuspended in
buffer composed of (mM): Tris-HCl 50, EDTA 1, and MgCl2 3, pH 7.4, to
yield protein concentration of 2–4 mg/ml. Membrane preparations were
aliquoted and stored at 80 °C. Binding was initiated by the addition of
20	g ofmembrane protein into glass tubes containing 0.1 nM [35S]GTPS,
10 	M GDP in GTPS binding buffer (50 mM Tris-HCl, 100 mM NaCl, 3
mM MgCl2, 0.2 mM EGTA, 0.1% bovine serum albumin, pH 7.4). Nonspe-
cific binding was assessed in the presence of 20 	M unlabeled GTPS.
Binding assays were performed for 90 min at 30 °C with various concen-
trations of WIN 55212-2, CP55,940, anandamide, and SR141716A in a
total volume of 500 	l. Free and bound radioligands were separated by a
rapid filtration through Whatman GF/C filters. Filters were shaken for
1 h in 6ml of scintillation fluid (Fisher), and radioactivity was determined
by a liquid scintillation counter.
Expression in Oocytes and Recordings—This technique was per-
formed as described previously (31). Briefly, 0.013 pg of GIRK1 and
GIRK4 and 25 ng of CB1 (wild type or mutant) cRNAs were co-injected
using a micromanipulator (Drummond Scientific Co., Broomall, PA)
into Xenopus laevis oocytes (XenopusOne, Dexter, MI). Recordings were
performed after 7–9 days of incubation in 0.5 L-15 media (Sigma)
supplemented with L-glutamine and antibiotics. For recordings, the
eggs were placed in a chamber (total volume 200 ml) and perfused at 4
ml/min with LK (2 mM KCl, 96 mM NaCl, 2 mM CaCl2, 1.8 mM MgCl2,
and 5 mM HEPES, pH 7.5), HK (96 mM KCl, 2 mM NaCl, 2 mM CaCl2,
1.8 mM MgCl2, and 5 mM HEPES, pH 7.5), or HK plus drug. Bovine
serum albumin (3 	M) was added to all drug solutions to minimize
absorption of cannabinoid compounds to the perfusion system. Oocytes
were impaled with two microelectrodes filled with 3 M KCl and were
voltage-clamped at reported voltages using an Axon GeneClamp ampli-
fier (Axon Instruments, Foster City, CA). Currents were filtered at 10
Hz, collected, and analyzed using a Macintosh Centris 650 containing a
16-bit analog-digital interface board and voltage-clamp software run-
ning under the IGOR graphics environment (Wavemetrics, Lake
Oswego, OR). Oocytes were voltage clamped at 80 mV and super-
fused in a low potassium (LK) solution containing 96 mM Na and 2
mM K. When a high potassium (HK) solution containing 96 mM K
and 2 mM Na was exchanged for LK, an inward current was pro-
duced and termed IHK. IHK represents the basal activity of GIRK1/4
channels. This current reached a plateau with 30 s (31). At this
point application of the cannabinoid agonists (WIN 55,212-2 or anan-
damide) in HK further enhanced the inward current. This agonist-
induced current was named IAg. Concentration-response curves were
generated by nonlinear regression of log percent concentration en-
hancement data (IAg/IHK  100) with the use of the GraphPad Prism
program (GraphPad, San Diego, CA).
Statistical Analyses—The EC50 and Emax values were calculated by
unweighted least squares nonlinear regression of log concentration values
versus percent effect. Significant differences were determined (GraphPad
Prism) using analysis of variance or the unpaired Student’s t test, where
TABLE I
Binding profile of wild type and mutant cell lines used in this study
The Kd and Bmax values were obtained from saturation experiments using 	
3H
CP55,940 performed on membranes prepared from wild type and
mutant HEK cell lines as described previously (1). Inhibition constants (Ki) values were obtained from competitive binding experiments using the
listed ligands versus 	3H
CP55,940 (1). Data are the means and corresponding 95% confidence limits of three independent experiments each
performed in triplicate.
Cell line CP55,940, Kd (nM)/Bmax WIN 55,212-2, Ki (nM) Anandamide, Ki (	M) SR141716A, Ki (nM)
pmol/mg
CB1 1.5 (0.53–2.4)/4.4 (3.5–5.3) 12 (7.0–20) 0.3 (0.1–0.6) 4.8 (2.2–10)
F3.25(190)A 5.5 (0.3–10)/3.2 (1.9–4.5) 15 (3.7–49) 1.8a (0.6–5.6) 9.6 (4.6–20)
F3.36(201)A 2.3 (0.6–4.1)/5.2 (3.6–6.9) 107a (44–261) 0.3 (0.1–1.1) 14a (7.3–29)
W5.43(280)A 5.4 (1.2–9.5)/1.9a (1.1–2.6) 199a (43–914) 0.3 (0.2–0.7) 46%a displacement at 5 	M
W6.48(357)A 3.2 (2.0–4.4)/4.4 (3.8–5.2) 45a (22–92) 0.3 (0.1–0.5) 33a (23–45)
a Values indicate statistically significant differences from wild type (p  0.05).
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suitable. Bonferroni-Dunn post-hoc analyses were conducted when appro-
priate. p values 0.05 defined statistical significance.
RESULTS
The TMH3-4-5-6 Aromatic Microdomain at the CB1
Receptor; Comparison of R and R* State Models in the
Absence of Ligand
CB1 R State—Fig. 2A illustrates key features of the CB1
TMH bundle model in the inactive (R) state in the TMH3-4-5-6
region. One of the significant features of this model is a salt
bridge between K3.28(193) and D6.58(367) (N-O distance 2.6
Å; N-H-O angle  159°) (51). This salt bridge is made possible
by the profound flexibility in TMH6 due to the presence of
G6.49 in the CWXP motif of TMH6 (25). The TMH3-4-5-6
region of the R bundle in the absence of ligand is characterized
by a W6.48(357)/F3.36(201)/W5.43(280)/Y5.39(276)/W4.64(256)
aromatic cluster in which W6.48(357) stacks with F3.36(201)
(d  5.3 Å,   90°), whereas F3.36(201) stacks with
W5.43(280) (d  5.6 Å,   40°). W5.43(280) also has an off-set
parallel stack with Y5.39(276) (d  5.9 Å,   0°), whereas
Y5.39(276) stacks with W4.64(256) (d  6.5 Å,   90°) (see
“Experimental Procedures” for definitions of d and ).
Residue 3.25 (190) does not stack with the other aromatic
residues in the TMH3-4-5-6 region but still appears to be an
important residue. In the R bundle, F3.25(190) is located di-
rectly extracellular to K3.28 and is close enough to K3.28 to be
able to form a cation- interaction with K3.28 (193) (NZ-cen-
troid distance, r  3.1 Å, CE-centroid distance, r  4.9 Å; see
“Experimental Procedures” for definitions of distances). In the
R state, the 1 for K3.28 (193) and for F3.25(190) is trans.
CB1 R* State—Fig. 2B illustrates key features of the CB1
TMH bundle model in the active (R*) state in the TMH3-4-5-6
region. The conformational changes that occur upon receptor
activation result in rotations of TMH3 and -6 as well as a
change in the conformation of TMH6 (by moderation of its
proline kink angle) (6–8, 10). In our models, both W6.48(357)
and F3.36(201) undergo a change in their 1 values from R to
R*. 1 in W6.48(357) changes from g to trans and 1 of
F3.36(201) changes from trans to g (see “Experimental Pro-
cedures” for definition of 1). In the R* TMH bundle, the
K3.28(193) and D6.58(367) salt bridge is broken (N-O dis-
tance  16.8 Å) because TMH3 and -6 rotate (counterclockwise
from extracellular view) during the R to R* transition (i.e.
activation) (26, 32). K3.28(193) has rotated away from
D6.58(367) toward TMH2/TMH7, and D6.58(367) has rotated
toward the TMH5–6 interface and is raised higher above the
ligand-binding pocket due to the moderation of the TMH6
proline kink angle. The W6.48(357)/F3.36(201)/W5.43(280)/
Y5.39(276)/W4.64(256) aromatic cluster present in the inac-
tive state in the absence of ligand also undergoes re-
arrangement, with F3.36(201) no longer part of this cluster.
In the TMH3-4-5-6 region of R* in the absence of ligand,
W6.48(357) and W5.43(280) form an off-set parallel aromatic
stacking interaction with each other (d  4.9 Å,   30°).
W5.43(280) also stacks with Y5.39 (d  6.6 Å,   60°),
whereasY5.39 stacks with W4.64 (d  5.7 Å,   90°). This
series of aromatic stacking interactions results in a large
aromatic stack in R* comprised of W6.48(357)/W5.43(280)/
Y5.39(276)/W4.64(256). F3.36(201) (1  g) is not located
near another TMH3-4-5-6 aromatic residue in the R* bundle,
instead F3.36(201) is bounded by V3.40(205), V3.32(197), and
L6.44(353).
As stated above, in the R* state, the rotation of TMH3 upon
activation causes K3.28(193) to point toward TMH2/TMH7,
and because F3.25(190) is one turn above K3.28(193), it also
now faces the TMH2/TMH7 region. The 1 for both K3.28(193)
and F3.25(190) is g in the R* bundle.
Ligand Binding
We have recently published mutation and modeling studies
of the CB1 TMH3-4-5-6 aromatic microdomain in which bind-
ing sites for the inverse agonist SR141716A and the CB1 ago-
nists WIN 55212-2 and anandamide were identified (1).
Functional Analysis of Mutant Receptors
We have shown previously that the aromatic residues
F3.36(201), W5.43(280), and W6.48(357) form specific interac-
tion sites in CB1 for aminoalkylindole agonist (WIN 55,212-2)
and diaryl pyrazole inverse agonist/antagonist (SR141716A)
ligands but not for endogenous (anandamide) and bicyclic can-
nabinoid (CP55,940) agonists (1). When the aromatic residues
were individually mutated to alanine, a significant reduction in
ligand binding affinity was only observed in the presence of
WIN 55,212-2 and SR141716A but not CP55,940 and anand-
amide. The study presented here is a detailed functional anal-
ysis of these mutant receptors using two different cellular
backgrounds. The mutants were studied in stable cell lines
created in HEK cells or in oocytes where the mutant proteins
were expressed transiently. The mutations were analyzed in
two ways. Direct receptor-G protein stimulation in HEK cells
was assessed using [35S]GTPS binding, and G protein stimu-
lation downstream of the receptor was evaluated by measuring
enhancement of GIRK channel activity in oocytes.
F3.36A(201)—The F3.36A(201) mutation produced a signifi-
cant reduction in agonist-dependent activation produced by
WIN 55,212-2 (Fig. 3, A and B, and Tables II and III). This
could be observed at the level of direct receptor-G protein
stimulation (GTPS), and this outcome was even more pro-
found downstream at GIRK1/4 channels. The affinity of WIN
55,212-2 at F3.36A(201) was reduced 8.9-fold in HEK cells,
whereas the affinity of CP55,940 and anandamide was unaf-
fected (1). Even the addition of high concentrations of WIN
55,212-2 could not produce substantial receptor activation sug-
gesting the loss of affinity for the ligand, produced by the
mutation, was not solely responsible for decreased activation.
To strengthen this conclusion further, CP55,940 and anandam-
ide were also tested because the mutation to alanine at
F3.36(201) had no effect on the affinity of these ligands for the
receptor (Table I). Full receptor activation could also not be
produced with CP55,940 (see Fig. 3D and Table II) or with
anandamide (see Fig. 3C and Table III).
We next examined whether observed reductions in function
were the result of a constitutively activated receptor. The CB1
receptor has been shown to have a high level of agonist-inde-
pendent activation (i.e. constitutive activity) in transfected cell
lines where the reporter system is a G protein-activated ion
channel or an intracellular kinase (33, 34). The ability of CB1 to
activate G proteins in the absence of exogenously applied ago-
nist has also been shown for native CB1 receptors in human
and rat brain (35, 36). Kearn and co-workers (37) have esti-
mated that in WT CB1, the receptor populations are 70% inac-
tive state (R) and 30% active state (R*).
Agonist-independent activation of GPCRs can be assessed by
measuring basal turnover of [35S]GTPS in transfected cells
and by comparing the IHK of GIRK1/4 in injected oocytes (38,
39). Consistent with previous findings (39), we found a 56%
increase (WT CB1  1055  58 dpm, untransfected  675* 
73 dpm) in agonist-independent activation of [35S]GTPS in
HEK cells expressing WT CB1 compared with untransfected
cells (Fig. 7 and Table IV). When the agonist-independent
GTPS activity of F3.36A(201) was compared with WT CB1, a
73% increase (F3.36(201)A  1825  138 dpm, WT CB1 
1055  58 dpm) was observed with the mutant (Fig. 7 and
Table IV). A 62% increase was also observed when IHK or basal
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activity of GIRK1/4 was evaluated between F3.36A(201) and
WT CB1 (Fig. 8 and Table IV). Although the amount of receptor
expressed in oocytes used for the GIRK assay cannot be deter-
mined, the Bmax values for the WT and F3.36(201)A cell lines
used for the GTPS assay were not statistically different from
one another (WT CB1 Bmax  4.4 (3.5–5.3) pmol/mg;
F3.36(201)A-Bmax  5.2 (3.6–6.9) pmol/mg; Table I). Thus, the
73% increase (relative to WT) in the level of GTPS binding
seen in the HEK cells stably transfected with F3.36(201)A
cannot be attributed to an overexpression of mutant receptor
protein (Table I). These combined data strongly suggested the
F3.36A(201) mutant receptor had even greater constitutive
activity than WT CB1. To further support this hypothesis, the
properties of the mutant receptor were evaluated using the
CB1-selective inverse agonist SR141716A. An inverse agonist
should reduce the basal activity of the constitutively activated
mutant receptor because the inverse agonist will force the
receptor to adopt an inactive conformation; this was the case
(Figs. 3E and 7). Furthermore, compared with WT CB1 the
inverse agonist response of SR141716A at F3.36A(201) was
significantly increased (Fig. 3E). No inverse agonism was pro-
duced at WT CB1 except at the highest (5 	M) concentration
(17  2%, n  3) (Fig. 3E). However, inhibition of GTPS
binding occurred with F3.36(201)A in the presence of nanomo-
lar concentrations of SR141716A with EC50 and Emax values of
0.6 (0.1–3.2) nM and 24 (30 to 18) %, respectively.
Modeling studies also suggest that the F3.36(201)A mutant
should be constitutively active, if it is assumed that changes in
FIG. 3. Comparison of WT CB1 (f) and F3.36(201)A (Œ) receptor activation. WIN 55,212-2 (A), CP55,940 (D), and SR141716A (E) were
used for concentration-response analysis of [35S]GTPS binding in HEK cell membranes expressing wild type or mutant receptor protein. ●
represents the WT CB1 response to SR141716A. Each data point shown is the mean  S.E. of at least three independent experiments performed
in triplicate. WIN 55,212-2 (B) and anandamide (C) were also used for concentration-response analysis in oocytes co-expressing GIRK1/4 and CB1
(WT or mutant) cRNAs. The amount of RNA injected and the recording protocol are described under the “Experimental Procedures.” Each data
point in the concentration-response curve is the mean  S.E. of 4–15 determinations made from at least two batches of oocytes.
TABLE II
Cannabinoid agonist stimulation of 	35S
GTPS from membranes prepared from wild type and mutant cell lines
Data shown are the means  S.E. of at least three experiments performed in triplicate.
Agonist Cell line EC50 Emax
nM %
WIN 55,212-2 CB1 5.3 (2.8–10) 76 (69–82)
F3.25(190)A 33a (21–53) 74 (68–80)
F3.36(201)A 9.3 (3.2–26) 45a (41–51)
W5.43(280)A 1,300a (309–5,521) 81 (40–121)
W6.48(357)A 61a (40–94) 147a (133–162)
CP55,940 CB1 0.5 (0.2–1.5) 38 (32–43)
F3.36(201)A 0.3 (0.1–0.6) 24a (21–26)
W5.43(280)A 33a (5.9–85) 53 (34–71)
W6.48(357)A 1.3 (0.8–2.2) 100a (94–107)
a Values indicate statistically significant differences from wild type (p  0.05).
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the TMH3-4-5-6 aromatic cluster influence the state preference
for the receptor. The loss of aromaticity at 3.36 (i.e. in the
F3.36(201)A mutation) would result in the inability of
W6.48(357) to participate in the extended aromatic cluster to
which it belongs in WT CB1. Specifically, this mutation would
reduce the aromatic cluster present in the R state of WT CB1
fromW6.48(357)/F3.36(201)W5.43(280)/Y5.39(276)/W4.64(256)
to W5.43(280)/Y5.39(276)/W4.64(256) (Fig. 2A). However, the
F3.36(201)A mutation would not have an effect on the R* state,
as F3.36(201) is not part of the aromatic cluster in the R* state
of CB1 (Fig. 2B). Thus, the W6.48(357)/W5.43(280)/Y5.39(276)/
W4.64(256) cluster present in the R* state would be unchanged
by the F3.36(201)A mutation. The net result of the F3.36(201)A
mutation, therefore, should be a de-stabilization of the inactive
state of CB1, leading to increased constitutive activity.
W5.43(280)A—The EC50 values reported in Tables II and III
show that the potency of WIN 55,212-2 at the W5.43(280)A
mutant was reduced 245- and 16.8-fold when this receptor was
studied by using GTPS binding or by measuring enhancement
of GIRK channel activity, respectively (Fig. 4, A and B and
Tables II and III).
The full effect of WIN 55,212-2, however, at the W5.43(280)A
mutant receptor could be achieved at higher concentrations.
The substantial reductions in potency, in two cell systems, may
be due in part to the decreased affinity of WIN 55,212-2 at
W5.43(280)A. The affinity of WIN 55,212-2 at W5.43(280)A was
reduced 16.8-fold in HEK cells, whereas the affinity of
CP55,940 and anandamide was unaffected (Table I) (1). Be-
cause the affinities of CP55,940 and anandamide were unaf-
fected at this mutation, the functional responses produced by
these ligands were tested at W5.43(280)A to determine
whether the effects observed in the presence of WIN 55,212-2
were primarily a result of a reduction in affinity at the mutant
receptor. As shown in Fig. 4, C and D, there was a substantial
reduction in the potency of both anandamide and CP55,940 at
W5.43(280)A. It is clear in Table I, however, that the Bmax of
the W5.43(280)A mutant was statistically lower than that of
WT CB1. Lower receptor expression levels can produce a right-
ward shift in plots of response versus log[ligand] compared with
a system in which a greater amount of receptor protein is
expressed, despite the fact that the ligand has equal affinity in
both systems. Thus, the reduced expression level of the
W5.43(280)A mutant compared with WT CB1 may explain the
rightward shifts in Fig. 4, C and D, seen for anandamide and
CP55940 (40). There were no significant changes in agonist-
independent activation of W5.43(280)A in either cell system
tested (Figs. 7 and 8 and Table IV).
W6.48A(357)—The EC50 values reported in Tables II and III
show that the potency of WIN 55,212-2 at the W6.48(357)A
mutant was reduced 12- and 1.8-fold when this receptor was
studied using GTPS binding or by measuring enhancement of
GIRK channel activity, respectively (Fig. 5, A and B, and Ta-
bles II and III). However, the loss of potency observed with
GIRK channel activity was not significant. The effects on po-
tency may be due to the decreased affinity of WIN 55,212-2 at
W6.48(357)A. The affinity of WIN 55,212-2 at W6.48(357)A was
reduced 3.8-fold in HEK cells, whereas the affinity of CP55,940
and anandamide was unaffected (Table I) (1). Because the
affinity of CP55,940 and anandamide was unaffected at this
mutation, the functional responses produced by these ligands
were tested at W6.48A(357). As shown in Fig. 5, C and D, and
Tables II and III, there was no significant reduction in the
potency of either CP55,940 or anandamide at W6.48A(357).
These data suggest the loss in potency observed for WIN
55,212-2 stimulation of GTPS binding at W6.48(357)A was the
result of the selective loss of affinity for WIN 55,212-2 at this
mutant receptor. It should be noted that a comparison of the
shifts in potency for WIN 55,212-2 at both W6.48(357)A and
W5.43(280)A demonstrate the GTPS assay is more sensitive
to this observable effect compared with studying GIRK channel
activity (Figs. 4, A and B and Fig. 5, A and B, and Tables II and
III).
Most interestingly, the maximum stimulation of GTPS ac-
tivity produced by WIN 55,212-2 at W6.48(357)A was signifi-
TABLE IV
Agonist-independent activation (or basal activity) of WT CB1 and
mutant receptors assessed by measuring basal turnover of [35S]GTPS
binding or the IHK of GIRK1/4
(SR) indicates reduction of basal 	35S
GTPS binding in the presence
of 1 	M SR141716A. 	35S
GTPS binding data shown are the mean 
S.E. of at least three experiments performed in triplicate. To determine
basal potassium channel activity or IHK, a large number of oocytes (n 
20–46) were analyzed for each condition from at least two batches of
oocytes.
Measure Cell line dpm
Basal 	35S
GTPS WT CB1 1055  58
Untransfected HEK 675a  73
F3.25(190)A 1114  55
F3.36(201)A 1825a  138
F3.36(201)A (SR) 1042  69
W5.43(280)A 891  45
W6.48(357)A 1263  12
Cell line IHK
	A
IHK of GIRK1/4 WT CB1 0.74  0.12
F3.25(190)A 0.87  0.12
F3.36(201)A 1.2a  0.09
W5.43(280)A 0.92  0.14
W6.48(357)A 0.79  0.09
a Values indicate statistically significant differences from wild type
(p  0.05).
TABLE III
Cannabinoid agonist stimulation of GIRK1/4 currents in oocytes expressing wild type and mutant CB1 proteins
The amount of RNA injected and the recording protocol are described under “Experimental Procedures.” Each data point in the concentration-
response curve is the mean  S.E. of 4–15 determinations made from at least two batches of oocytes.
Agonist Cell line EC50 () Emax
nM %
WIN 55,212-2 WT CB1 13 (4–47) 127 (106–148)
F3.25(190)A 25 (11–61) 116 (101–132)
F3.36(201)A 24a (8) at 1 	M
W5.43(280)A 218a (66–723) 129 (93–165)
W6.48(357)A 23 (12–44) 121 (104–137)
Anandamide WT CB1 3 (2–5) 93 (90–115)
F3.25(190)A 47a (30–75) 59a (41–76)
F3.36(201)A 8a (0.5) at 1 	M
W5.43(280)A 13a (6–36) 58a (48–73)
W6.48(357)A 5 (2–16) 114 (101–127)
a Values indicate statistically significant differences from wild type (p  0.05).
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cantly enhanced compared with WT CB1 (Fig. 5A and Table II).
To determine whether this effect was specific for aminoalky-
lindoles, the bicyclic cannabinoid CP55,940 was also tested at
W6.48(357)A. As observed with WIN 55,212-2, CP55,940 also
produced enhanced stimulation of GTPS activity at
W6.48(357)A compared with WT CB1 (Fig. 5D). The enhanced
activity of WIN 55,212-2 at W6.48(357)A was not observed
when GIRK channel activity was measured (Fig. 5B).
There were no significant changes in agonist-independent
activation of W6.48(357)A in either cell system tested (Figs. 7
and 8 and Table IV). Consistent with unchanged constitutive
activity, the response to the inverse agonist at W6.48(357)A
was not different from the response of WT CB1 to the inverse
agonist (Fig. 5E). Modeling studies also suggest that the
W6.48(357)A mutant should not be constitutively active, if it is
assumed that changes in the TMH3-4-5-6 aromatic cluster
influence the state preference for the receptor. The W6.48A
mutation will affect the TMH3-4-5-6 aromatic cluster in both
the R and R* states. In the R state, the W6.48A mutation will
result in the loss of one aromatic stacking interaction, i.e. the
W6.48(357)/F3.36(201)/W5.43(280)/Y5.39(276)/W4.64(256)
cluster in R will become a F3.36(201)/W5.43(280)/Y5.39(276)/
W4.64(256) cluster in the mutant. In the R* state, the
W6.48(357)/W5.43(280)/Y5.39(276)/W4.64(256) cluster present
in the R* state will become a W5.43(280)/Y5.39(276)/
W4.64(256) cluster in the mutant. Because aromatic stacking
in both the R and R* states will be equally impacted, it is
reasonable to expect that the W6.48A mutant will not produce
a change in basal levels for the W6.48A mutant relative to WT
CB1, and this is what was seen experimentally.
F3.25(190)A—We previously reported that F3.25(190) is not
part of the binding site of WIN 55,212-2, SR141716A, or
CP55,940 but is a part of the anandamide-binding pocket (1).
When F3.25(190) was mutated to an alanine, a 6-fold reduction
in binding affinity was observed in the presence of ananda-
mide, but no changes were observed in the presence of WIN
55,212-2, SR141716A, and CP55,940 (Table I). When GIRK
channel activity was measured there was a significant reduc-
tion in both the potency and efficacy of anandamide at
F3.25(190)A but no change in the presence of WIN 55,212-2
(Fig. 6, A and B, and Table III).
This result correlates with the binding data and receptor
modeling. The effect seen with anandamide is likely to be
related in part to the decreased affinity of anandamide for the
F3.25(190)A mutant, as F3.25(190) is part of the anandamide-
binding site (1). Anandamide stimulation of GTPS turnover,
in HEK cells transfected with F3.25(190)A, could not be meas-
ured because the partial agonist nature of the endogenous
ligand results in a nonsignificant amount of GTPS stimula-
tion (41). Therefore, the findings with anandamide and the
GIRK channel activity could not be compared with GTPS
stimulation because anandamide did not produce a significant
functional response in HEK cells. There was a 6.2-fold decrease
FIG. 4. Comparison of WT (f) CB1 and W5.43(280)A (Œ) receptor activation. WIN 55,212-2 (A) and CP55,940 (D) were used for
concentration-response analysis of [35S]GTPS binding in HEK cell membranes expressing wild type or mutant receptor protein. Each data point
shown is the mean  S.E. of at least three independent experiments performed in triplicate. WIN 55,212-2 (B) and anandamide (C) were also used
for concentration-response analysis in oocytes co-expressing GIRK1/4 and CB1 (WT or mutant) cRNAs. The amount of RNA injected and the
recording protocol are described under the “Experimental Procedures.” Each data point in the concentration-response curve is the mean  S.E. of
4–15 determinations made from at least two batches of oocytes.
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in the potency of WIN 55,212-2 when receptor activation was
assessed by measuring GTPS activity.
These agonists do not exhibit affinity changes from WT in
the F3.25(190)A mutant. However, the effects observed on po-
tency and/or efficacy reported here for WIN 55212-2 at the
F3.25(190)A mutant may be related to the general role
F3.25(190) plays in positioning K3.28 in the TMH bundle. As is
clear from Fig. 2, F3.25(190) is just above K3.28 in the inactive
state of CB1 and has a cation- interaction (r  5 Å) with this
residue. Gallivan and Dougherty (29) have reported that 14.5%
of all cation- interactions found in the “Protein Data Bank
Select” list of Sander and co-workers (42, 43) represent such
Lys-Phe interactions. Our modeling studies suggest that these
residues move in concert with each other, as they both have
trans 1s in the R state and g 1s in the R* state. F3.25(190)
may act as a chaperone of K3.28 to position it in the correct
location in R* for ligand interaction and to shield it from the
extracellular milieu in the R state. Because residue positions in
TMH3 R* may be changed in the absence of aromaticity at
position 3.25, it is possible that ligands that do not bind to
F3.25(190) can have their potency and/or efficacy affected by
the F3.25(190)A mutation.
There were no significant changes in agonist-independent
activation of F3.25(190)A in either cell system tested (Fig. 7
and Fig. 8 and Table IV). F3.25(190) is not part of the TMH3-
4-5-6 aromatic cluster that characterizes the R and R* states of
CB1 (see Fig. 2). Therefore, the mutation of this aromatic
residue to a nonaromatic residue would not be expected to
affect basal levels.
Toggle Switch Residues
Fig. 9 illustrates the relationship between F3.36(201) and
W6.48(357)in the R and R* states of CB1. In the context of the
inactive state model (see Fig. 9, left), F3.36(201) (1  trans)
is located opposite W6.48(357)(1  g) and has an aromatic
stacking interaction with W6.48(357) that would prevent the 1
of W6.48(357) from changing from g to trans, thus stabilizing
TMH6 in its inactive conformation. In the active state of CB1,
F3.36(201) and W6.48(357) change conformations
(F3.36(201)(1  trans)/W6.48(357)(1  g) 3 F3.36(201)(1
 g)/W6.48(1 trans)) in order to rotate past each other and
F3.36(201) (1  g) and W6.48(357) (1  trans) are located
too far apart in R* to interact with each other (see Fig. 9, right).
Conformational Memories Study of WT TMH6 Versus
W6.48A TMH6—TMH6 in the class A GPCRs contains the
highly conserved sequence motif, CWXP. This proline contain-
ing region of TMH6 is thought to act as a flexible hinge during
GPCR activation (44). Proline residues are known to perturb
the structure of helices by introducing a kink between the
segments preceding (pre-proline helix) and following the pro-
line residue (post-proline helix). The distortion of the helical
structure results from the avoided steric clash between the ring
of the proline at position (i) and the backbone carbonyl at
position (i  4), as well as the elimination of helix backbone
FIG. 5. Comparison of WT (f) CB1 and (Œ) W6.48(357)A receptor activation. WIN 55,212-2 (A), CP55,940 (D), and SR141716A (E) were
used for concentration-response analysis of [35S]GTPS binding in HEK cell membranes expressing wild type or mutant receptor protein. ●
represents the WT CB1 response to SR141716A. Each data point shown is the mean  S.E. of at least three independent experiments performed
in triplicate. WIN 55,212-2 (B) and anandamide (C) were used for concentration-response analysis in oocytes co-expressing GIRK1/4 and CB1 (WT
or mutant) cRNAs. The amount of RNA injected and the recording protocol are described under the “Experimental Procedures.” Each data point
in the concentration-response curve is the mean  S.E. of 4–15 determinations made from at least two batches of oocytes.
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hydrogen bonds for the carbonyls at positions (i 3) and (i 4).
Both the departure from the ideal helical pattern and the
reduction in H-bond stabilization contribute to the observed
flexibility of a proline-containing -helix. Table V lists the
results of ProKink analyses of WT TMH6 CM output and the
W6.48A TMH6 CM output. This analysis yields values not only
FIG. 7. Agonist-independent activation of WT CB1 and mutant
receptors was assessed by measuring basal turnover of
[35S]GTPS binding. (SR) indicates reduction of basal [35S]GTPS
binding in the presence of 1 	M SR141716A. Data shown are the
mean  S.E. of at least three experiments performed in triplicate. The
* indicates statistically significant differences from wild type (p 0.05).
FIG. 8. Agonist-independent activity of GIRK1/4 channels was
assessed by measuring IHK in oocytes expressing WT or mutant
CB1 receptors. A large number of oocytes (n  20–46) were analyzed
for each condition from at least two batches of oocytes. The amount of
RNA injected and the recording protocol are described under the “Ex-
perimental Procedures.” The * indicates statistically significant differ-
ences from wild type (*, p  0.05, one-way analysis of variance).
FIG. 6. Comparison of WT (f) CB1 and F3.25(190)A (Œ) receptor activation. Anandamide (A) and WIN 55,212-2 (B) were used for
concentration-response analysis in oocytes co-expressing GIRK1/4 and CB1 (WT or mutant) cRNAs. The amount of RNA injected and the recording
protocol are described under the “Experimental Procedures.” Each data point in the concentration-response curve is the mean  S.E. of 4–15
determinations made from at least two batches of oocytes. C, WIN 55,212-2 was used for concentration-response analysis of [35S]GTPS binding
in HEK cell membranes expressing wild type or mutant receptor protein. Each data point shown is the mean  S.E. of at least three independent
experiments performed in triplicate.
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for the bend angle of this proline-containing helix but also the
wobble angles and face shifts for these helices. The bend angle
is the angle between the two parts when the helix is kinked
along its axis. The wobble angle is the angle that defines the
orientation of the post-proline helix in three-dimensional
space, with respect to the pre-proline helix. The face shift
measures the distortion that causes a twisting of the helix
“face” in such a way that amino acids that used to be on the
same side (face) of the helix are shifted and are on different
sides of the helix as a result of the bend (20).
The results of conformational memories calculations on WT
CB1 and the W6.48A mutant are summarized in Table V. In
each case, X-cluster identified two major clusters of conform-
ers. The first cluster contained TMH6s with large bend angles,
whereas the second cluster contained TMH6s with straighter
helices (i.e. smaller bend angles). Because TMH6 is more
kinked in the inactive state (R) and straightens in the activated
state (R*), these two clusters are labeled R and R* in Table V
(12). The ProKink program (20) was used to analyze each helix
within each cluster in terms of bend angle, wobble angle, and
face shift and to compute averages and standard deviations for
each cluster.
For WT CB1, cluster 1 contained 40 members with an
average proline bend (kink) angle of 75.9  1.0°, whereas
cluster 2 contained 51 members with average bend angle of
33.7  1.1°. The TMH6 used in our CB1 R model was selected
from the more bent cluster, cluster 1, whereas the TMH6
used in our CB1 R* model was selected from the straighter
cluster, Cluster 2 (see “Experimental Procedures”). For the
TMH6 W6.48A mutant, cluster 1 contained 19 members with
an average proline bend (kink) angle of 74.0  1.0°, whereas
cluster 2 contained 72 members with an average proline bend
angle of 36.8  1.2°.
At the 0.01 level, the difference of population means for the
kink, wobble, and face shift angles for the W6.48A mutant
reported in Table V were not significantly different from the
corresponding measures in WT CB1, except for the R* wobble
angle. Here the W6.48A R* wobble angle (105.6  3.4°) was
found to be significantly different from the WT R* wobble angle
(120.5  4.6°) at the 0.01 level. Fig. 10 illustrates the steric
consequence of this 15° difference in wobble angle. In the R to
R* transition, the salt bridge between R3.50 and D/E6.30 is
thought to be broken via a conformational change in TMH6
mediated by the flexible hinge region (CWXP motif) of TMH6.
Fig. 10 shows that D6.30 in the W6.48A mutant is capable of
pulling further away from the intracellular end of TMH3 and
R3.50 than is D6.30 in WT TMH6.
DISCUSSION
Mutation of the toggle switch residues, F3.36(201) and
W6.48(357), yielded perhaps the most interesting results of all
aromatic microdomain mutations reported here. Mutation of
F3.36(201) resulted in elevated basal signaling (increased con-
stitutive activity) and reduced ligand efficacies. Mutation of
W6.48(357) resulted in unaltered basal signaling but greatly
enhanced ligand efficacies. These results are discussed below.
F3.36(201)A Mutation—F3.36(201) is revealed here to be a
key residue both for ligand binding and for CB1 activation. One
of the significant results in the work reported here is that
although WT CB1 and the F3.36(201)A mutant have statisti-
cally equivalent protein expression levels in HEK293 cells (see
Table I), an F3.36(201)A mutation results in a statistically
significant higher level of ligand-independent activation of CB1
(i.e. higher basal levels, increased constitutive activity) as as-
sessed by [35S]GTPS binding. In addition to the demonstra-
tion of elevated basal levels, another way to test for constitutive
activity in a mutant receptor is to examine the effects on basal
signaling produced by an inverse agonist. If the receptor is
constitutively active, then the inverse agonist should be able to
reduce basal levels (i.e. reduce [35S]GTPS binding). We have
shown here by assessing basal turnover of [35S]GTPS binding,
that the CB1 inverse agonist, SR141716A reduces basal signal-
ing in the F3.36(201)A mutant, and this effect is statistically
significant (p  0.05) (see Fig. 7 and Table IV). Another tradi-
tional expectation of constitutively active receptors is that the
affinities of agonists should increase, and the affinities of in-
verse agonists should decrease due to the shift in the receptor
population toward R*. The majority of GPCR mutations that
have led to constitutive activity has been mutations in the
intracellular half-of the TMH bundle, away from the ligand-
binding pocket. Very typically, these have been mutations to
TMH6 (45). However, the mutation that produced an increase
in constitutive activity here, F3.36(201)A, involves a key resi-
due in the ligand-binding pocket. For this reason, measured
ligand affinities for agonists, for example, would be the result of
two opposing factors as follows: an increase in affinity due to
the higher percentage R* in the F3.36(201)A mutant, but a
FIG. 9. The relationship between F3.36(201) and W6.48(357) in
the inactive (R) and active (R*) states of CB1 as predicted by
molecular modeling is illustrated here. The major view is from
TMH5 looking toward TMHs3/6. Left, in the R state, W6.48(357) adopts
a g 1, whereas F3.36(201) adopts a trans 1. In this arrangement,
W6.48(357) and F3.36(201) are engaged in an aromatic stacking inter-
action that stabilizes the R state. By analogy with Rho, the CB1-inactive
state is also characterized by a salt bridge between R3.50(215) and
D6.30(339) at the intracellular side of CB1 that keeps the intracellular
ends of TMH3 and 6 close (3). The TMH6 kink extracellular to
W6.48(357) permits a hypothesized salt bridge between K3.28(193) and
D6.58 (367) to form (51). This salt bridge is made possible by the
profound flexibility in TMH6 due to the presence of G6.49(358) in the
CWXP motif of TMH6 (25). Right, in the R* state, W6.48(357) and
F3.36(201) have moved apart due to rotation of TMH3 and -6 during
activation. W6.48(357) has adopted a trans 1 and has moved toward
the viewer and F3.36(201) has adopted a g 1 and has moved away
from the viewer. The R3.50(215)/D6.30(339) salt bridge is broken, and
the proline kink in TMH6 has moderated. Inset, this inset provides an
extracellular view of CB1. Here it is clear that in R, F3.36(201) and
W6.48(357) are engaged in an aromatic stacking interaction, but in R*,
F3.36(201) and W6.48(357) are no longer close enough to interact.
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decrease in affinity (some likely more than others depending on
binding site) due to a change in the ligand-binding site inter-
actions and/or in the binding pocket itself. For this reason, it is
not appropriate to use a shift in ligand affinities as a test for
constitutive activity here.
The W6.48(357)/F3.36(201) Toggle Switch in WT CB1—In
recently published Monte Carlo/stochastic dynamics calculations
on the inactive state of CB1, we found that one of the most
persistent aromatic stacking interactions in the inactive state of
CB1 is the F3.36(201)/W6.48(357) interaction (46). Models of the
CB1 inactive (R) and active (R*) TMH bundles illustrated here in
Fig. 9 show that in the inactive state residues W6.48(357)(1 
g) and F3.36(201) (1 trans) are engaged in a direct aromatic
stacking interaction. In this interaction, F3.36(201) appears to
serve the function of confining W6.48(357) to the g 1 rotamer
state and restricting movement of W6.48. In Rho, the -ionone
ring of 11-cis-retinal appears to serve the same function as
F3.36(201) in CB1 (3, 14) (Fig. 11), i.e. it sterically confines
W6.48(265) to the g 1 rotamer state and restricts the move-
ment of W6.48. Khorana and co-workers (13) have recently re-
ported one of the specific contacts that must break in Rho for
activation involves W6.48(265).
The conformational changes that occur upon receptor activa-
tion result in rotations of TMH3 and -6, as well as a change in
the conformation of TMH6 (by moderation of its proline kink
angle) (6–8,12). In the light-activated state of Rho, the -io-
none ring moves away from TMH F and toward TMH D where
it resides close to A4.58(169) (14). This movement releases the
constraint on W6.48, making it possible for W6.48(265) to un-
dergo a conformational change. For the CB1 receptor, counter-
clockwise (from the extracellular side) rotations of TMH3 and
-6 concomitant with activation (26, 32) would move F3.36(201)
and W6.48(357) past each other, with W6.48(357) moving to-
ward the viewer in Fig. 11 and F3.36(201) moving away from
the viewer (also see Fig. 9). Our modeling studies of the CB1
TMH bundle suggest that these rotations cannot take place
without a rotamer change for both W6.48(357) and F3.36(201)
due to steric clashing. In our models, activation is accompanied
by a 1 change in W6.48(357) from g3 trans and a 1 change
in F3.36(201) from trans 3 g (see above and Fig. 9). The
W6.48(357)/F3.36(201) interaction may act as the toggle switch
for CB1 activation, with W6.48(357) 1 g/F3.36(201) 1 trans
representing the inactive and W6.48(357) 1 trans/F3.36(201)
1 g representing the active state of CB1 (see Fig. 9). If this is
true, then mutation of F3.36(201) to a smaller residue, a resi-
due that is no longer a steric block to conformational change in
W6.48, would be expected to increase ligand-independent acti-
vation of CB1, and this is what is seen here experimentally.
Whereas the F3.36(201)A mutation leads to a high degree of
constitutive activity as is indicated in Fig. 7, this mutation also
results in the reduced efficacy for WIN and CP. This reduction
cannot be explained simply by reduced ligand affinity, as the
affinity of CP is not affected by this mutation, but its efficacy is
affected. It is possible that because the WT CB1 receptor itself
exhibits a high level of constitutive activity (33–35) and be-
cause the F3.36(201)A mutant exhibits an increase in consti-
tutive activity relative to WT CB1, the population of
F3.36(201)A mutant receptors is already shifted heavily to-
ward R*. This should not interfere with agonist binding, as
agonists have higher affinity for the R* state. However, this
would leave fewer receptors for ligands to activate, resulting in
a reduced Emax. This explanation is consistent with that of
Milligan (45) in a recent review concerning constitutive activity
of GPCRs. Milligan (45) noted that “a number of GPCRs do
seem to have significant levels of constitutive activity when
expressed in cell lines; in some cases, ligand-induced stimula-
tion of activity is relatively small compared with the signal in
the absence of ligand” (45). Alternatively, the profound effect
on ligand-dependent activation seen here for the F3.36(201)A
mutation may indicate that aromaticity at residue 3.36 is cen-
TABLE V
Results of conformational memories study of WT versus W6.48(357)A TMH6
No. members Bend angle Wobble angle Face shift
degrees  S.E. degrees  S.E. degrees  S.E.
WT
R CLS 1 40 75.9  1.0 47.5  8.2 60.3  4.1
R* CLS 2 51 33.7  1.1 120.5  4.6 57.8  7.0
W6.48(357)A
R CLS 1 19 74.0  1.0 39.6  1.8 60.9  2.2
R* CLS 2 72 36.8  1.2 105.6b  3.4 59.6  5.9
a CLS, cluster.
b Statistically significant difference from WT at the p  0.01 level.
FIG. 10. A comparison of conformational memories results for
WT CB1 TMH6 and the CB1 W6.48A TMH6 mutant. Left, here the
WT CB1 TMH6 R* cluster in green (51 members, see Table V) is shown
superimposed at their extracellular ends with the CB1 W6.48A TMH6
mutant R* cluster in yellow (72 members, see Table V). Statistically,
these two clusters differed only in their wobble angles (see Table V). The
view is through the plane of the proline kink. Here it is clear that the
wobble angle difference between the two groups results in a change in
the three-dimensional placement of the intracellular ends of these two
clusters. Right, a single helix from the WT R* cluster (bend angle 
33.8° and wobble angle  120.9°) and a single helix from the W6.48A
R* cluster (bend angle  35.5° and wobble angle  105.1°) are shown
here superimposed at their extracellular ends and positioned inside the
R* bundle. These helices have similar bend angles but differ by 15.8° in
their wobbles angles. The receptor state symbolized in the figure is the
activated (R*) state. The counterclockwise (from extracellular perspec-
tive) rotations of TMH3 and -6 and the straightening of TMH6 upon
activation result in the loss of the R3.50(215)/D6.30(339) salt bridge as
R3.50(215) and D6.30(339) move away from each other, opening a space
between TMH3 and -6 at their intracellular ends. It is clear here that
the change in wobble angle between the WT TMH6 (green) and W6.48A
mutant TMH6 (yellow) results in a greater displacement of D6.30(339)
relative to R3.50(215) in the W6.48A mutant (yellow).
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tral to the CB1 agonist-induced activation process and, conse-
quently, that mutation to a nonaromatic residue impairs the
function of this mutant CB1.
W6.48(357)A Mutation—The W6.48(357)A mutation did not
result in a statistically significant change in basal levels rela-
tive to WT CB1 (see Fig. 7). Our CB1 modeling studies have
shown that when W6.48(357) is mutated to alanine, helix pack-
ing allows F3.36(201) to interact with both A6.48 and L6.51.
This interaction would serve the same function as F3.36(201)
serves in WT CB1, i.e. effectively helping to stabilize TMH6 in
its inactive state conformation. Therefore, these results sug-
gest that basal levels should not change between WT CB1 and
the W6.48(357)A mutant. Looking at this from another per-
spective, consideration of the changes in the aromatic microdo-
main as a result of this mutation also suggests that aromatic
stacking in both the R and R* states will be equally impacted
by the W6.48(357)A mutation (see “Results”), it is reasonable
then to expect that the W6.48(357)A mutant will not produce a
change in basal levels relative to WT CB1, and this is what was
seen experimentally.
Although the W6.48(357)A mutation had no effect on basal
levels, it had noticeable effects on ligand-induced activation,
such that the efficacy of every ligand tested was enhanced. One
of the steps that has been proposed to occur during GPCR
activation is the breaking of an ionic lock (salt bridge) between
R3.50 and E/D6.30 that constrains the intracellular ends of
TMH3 and TMH6 to remain close in the inactive state (see Fig.
9, left) (10). GPCR activation appears to open a cleft at the
cytoplasmic face of a GPCR. Meng and Bourne (47) have de-
scribed activation as a “blossoming open” of the receptor at its
intracellular end. This opening permits G protein docking and
interaction with the cytoplasmic domains of the receptor. In
Rho, upon light activation, receptor residues in the IC-2 and
IC-3 loops have been cross-linked with the C terminus of the
G protein subunit and residues in the a4-b6 loop of G, indi-
cating that these sites on the G subunit are receptor-binding
sites (48). It is clear from the conformational memories results
reported here in Table V that the accessible conformations of
TMH6 are altered by the W6.48A mutation, with a 15° change
in the wobble angle for the population of W6.48(357)A TMH6
R*, compared with that of the R*WT CB1 TMH6 population. As
illustrated in Fig. 10, this change leads to TMH6 conformations
in which D6.30(339) in TMH6 is pulled further back from
R3.50(215) in TMH3, resulting in a wider “blossomed” intra-
cellular end of CB1 in the TMH6 W6.48(357)A mutant. Such a
wider opening may permit better coupling between the G pro-
tein and the W6.48(357)A mutant upon ligand activation, thus
resulting in increased Emax values.
This phenomenon of dramatic enhancement of Emax values
upon mutation of residue W6.48(357) has been seen previously
in the CCK-B gastrin receptor (49). Blaker and co-workers (49)
found that whereas a W6.48(346)A mutation did not affect
basal inositol phosphate production, this mutation affected the
functional activity of PD-135,158 (from 20  1% for WT CCK-B
to 43  5% in the W6.48(346)A mutant). An enhancement
of Emax has also been seen previously for mutations at other
loci. For example, in the 
-opioid receptor, Befort and co-
workers (50) found that a Y308F mutation in TMH7 resulted in
a marked increase in the efficacy of the potent agonist
BW373U86. Consistent with the interpretation of the CB1
W6.48(357)A mutation discussed above, these authors (50) at-
tributed this increase to a change in the receptor active state
conformation, such that the receptor can interact with hetero-
trimeric G proteins more effectively.
Conclusions—Modeling, mutation, and functional studies
undertaken to test the importance of the TMH3-4-5-6 aromatic
microdomain in ligand recognition and in the conformational
changes that accompany activation of CB1 suggest that a
F3.36(201)/W6.48(357)-specific contact is an important
constraint for the CB1-inactive state that may need to break
during activation. Modeling studies suggest that the
F3.36(201)/W6.48(357) contact can exist in the inactive state of
CB1 and be broken in the activated state via a 1 rotamer
switch (F3.36(201) trans, W6.48(357) g) 3 (F3.36(201) g,
W6.48(357) trans). The F3.36(201)/W6.48(357) interaction,
therefore, may represent a toggle switch for activation of CB1.
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